ArticleCancers2026
Validation of Preoperative Neoadjuvant Bevacizumab Therapy for Newly Diagnosed Glioblastoma via Comparative Analyses with Propensity Score Matching.
Article in Cancers, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Association between PLVAP downregulation and increased lymphocyte infiltration in newly diagnosed glioblastoma treated with bevacizumab.Brain tumor pathology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
BACKGROUND/
objectivesThe role of preoperative neoadjuvant bevacizumab (neoBev) in newly diagnosed glioblastoma (GB) remains controversial. We evaluated its impact on perioperative and survival outcomes and explored imaging-based associations with prognosis.
methodsWe retrospectively analyzed 33 patients with newly diagnosed GB who received preoperative neoBev (10 mg/kg; surgery performed 21-30 days later). A matched control cohort of 33 patients treated with standard chemoradiotherapy was selected using propensity score matching. Changes in Karnofsky Performance Status (KPS), extent of resection, and volumetric alterations on gadolinium-enhanced T1-weighted MRI (T1Gd) and FLAIR were assessed. Progression-free survival (PFS) and overall survival (OS) were compared.
resultsAll patients had GB (31 IDH-wild-type, 2 IDH-mutant). Median KPS improved after neoBev (71 to 83), while no improvement was observed in controls. After matching, median PFS and OS did not differ between the neoBev and control groups (7.4 vs. 8.6 months and 13.4 vs. 13.8 months, respectively). Exploratory analyses in the neoBev cohort showed that greater T1Gd volume reduction was associated with improved PFS and OS, whereas FLAIR changes were not.
conclusionsPreoperative neoBev did not improve survival compared with standard chemoradiotherapy. However, it was associated with improved functional status, and exploratory imaging findings suggested associations between early radiographic response and outcome. NeoBev should not be used routinely but may have a contextual role in selected patients with perioperative challenges.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.